Brain-derived neurotrophic factor/tropomyosin-related kinase B signaling pathway contributes to the aggressive behavior of lung squamous cell carcinoma

This publication has 52 references indexed in Scilit:

• Treating ALK-positive lung cancer—early successes and future challenges
  Nature Reviews Clinical Oncology, 2012
• High TrkB expression levels are associated with poor prognosis and EMT induction in colorectal cancer cells
  Journal of Gastroenterology, 2012
• Brain-derived neurotrophic factor expression predicts adverse pathological & clinical outcomes in human breast cancer
  Cancer Cell International, 2011
• Fibroblasts produce brain-derived neurotrophic factor and induce mesenchymal transition of oral tumor cells
  Oral Oncology, 2011
• TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells
  BMC Cancer, 2010
• Overexpression of TrkB promotes the progression of colon cancer
  APMIS, 2010
• TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma
  Oncogene, 2010
• Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
  New England Journal of Medicine, 2009
• Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
  The Lancet, 2005
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004